Guardian Pharmacy (GRDN) issues Q2 2025 earnings press release in 8-K filing

Rhea-AI Filing Summary

Guardian Pharmacy Services, Inc. furnished an 8-K to report that it issued a press release with its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference. The earnings information under Item 2.02 is furnished, not filed, under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001802255 0001802255 2025-08-11 2025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Guardian Pharmacy Services, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-42284		87-3627139
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

300 Galleria Parkway SE
Suite 800
Atlanta, Georgia		30339
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (404) 810-0089

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.001 per share		GRDN		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Guardian Pharmacy Services, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information set forth under this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Press Release dated August 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Guardian Pharmacy Services, Inc.
August 11, 2025		By:		/s/ David K. Morris
				Name:		David K. Morris
				Title:		Executive Vice President and Chief Financial Officer

FAQ

What did Guardian Pharmacy Services (GRDN) disclose in this 8-K?

Guardian Pharmacy Services disclosed that it issued a press release reporting its financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference in this current report.

Which period’s results are covered by Guardian Pharmacy Services’ August 11, 2025 release?

The August 11, 2025 press release from Guardian Pharmacy Services covers its financial results for the quarter ended June 30, 2025. This quarterly earnings information is referenced in the 8-K and furnished as Exhibit 99.1.

Is the earnings information in Guardian Pharmacy Services’ 8-K considered filed with the SEC?

The earnings information in this 8-K is being furnished, not filed, for purposes of Section 18 of the Exchange Act. It is not automatically incorporated into Securities Act filings unless specifically referenced there by the company.

What exhibit did Guardian Pharmacy Services (GRDN) attach to this 8-K?

Guardian Pharmacy Services attached Exhibit 99.1, which is the press release dated August 11, 2025 reporting financial results for the quarter ended June 30, 2025. Exhibit 104 covers the cover page interactive data file in Inline XBRL format.

Who signed Guardian Pharmacy Services’ August 11, 2025 8-K filing?

The August 11, 2025 8-K for Guardian Pharmacy Services was signed on the company’s behalf by David K. Morris, who is identified as Executive Vice President and Chief Financial Officer, acting as the duly authorized officer.